{"id":2553,"date":"2026-09-01T10:16:14","date_gmt":"2026-09-01T02:16:14","guid":{"rendered":"https:\/\/www.hanchorbio.com\/?post_type=news&#038;p=2553"},"modified":"2026-09-02T17:38:10","modified_gmt":"2026-09-02T09:38:10","slug":"hanchorbio-to-present-pipeline-strategy-at-2026-jefferies-apac-healthcare-conference","status":"publish","type":"news","link":"https:\/\/www.hanchorbio.com\/en\/news\/hanchorbio-to-present-pipeline-strategy-at-2026-jefferies-apac-healthcare-conference\/","title":{"rendered":"HanchorBio to Present Pipeline Strategy at 2026 Jefferies APAC Healthcare Conference"},"content":{"rendered":"<h2><strong>HanchorBio to Present Pipeline Strategy at 2026 Jefferies APAC Healthcare Conference<\/strong><\/h2>\n<h3><em>Management to discuss HCB101 as a clinical anchor, oncology platform expansion, and the emerging HCB206 autoimmune franchise<\/em><\/h3>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>TAIPEI, SHANGHAI, and SAN FRANCISCO \u2014\u00a0September 1, 2026<\/strong>\u00a0\u2014 HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that executive management will participate in the 2026 Jefferies APAC Healthcare Conference, taking place September 20\u201321, 2026, at Hilton Shanghai Zhangjiang Science Park in Shanghai.<\/p>\n<p>Executive leadership will present the continued evolution of the Company\u2019s proprietary FBDB\u2122 platform, highlighting clinical progress of the lead candidate HCB101, pipeline expansion across multispecific HCB301 and HCB303 oncology assets, and the emerging HCB206 autoimmune franchise.<\/p>\n<p>Key topics featured in the management presentation include:<\/p>\n<ul>\n<li><strong>HCB101 \u2014 Clinical Anchor:<\/strong> Updated clinical activity for HanchorBio\u2019s lead SIRP\u03b1-based macrophage-directed immunotherapy, including an 80% objective response rate (ORR) in the 5.12\u20138 mg\/kg mid-dose cohorts of second-line gastric\/gastroesophageal junction (GC\/GEJ) cancer treated with ramucirumab and paclitaxel.<\/li>\n<\/ul>\n<p>Additional clinical activity includes durable partial response beyond 80 weeks with HCB101 monotherapy in advanced HNSCC, a 50% ORR including a complete response in a Taiwan HNSCC study combining HCB101 with PD-1 blockade, and objective responses with prolonged disease control in colorectal cancer.<\/p>\n<ul>\n<li><strong>Oncology Platform Expansion:<\/strong> Progress across trispecific programs <strong>HCB301<\/strong> (SIRP\u03b1, PD-L1, TGF\u03b2) and <strong>HCB303<\/strong> (SIRP\u03b1, PD-L1, TIGIT\/PVR), together with rational combination strategies incorporating complementary therapeutic modalities including targeted small molecules, vaccines, bispecific immunotherapies, and antibody-drug conjugates (ADCs).<\/li>\n<li><strong>Autoimmune Franchise:<\/strong> Advancements of <strong>HCB206<\/strong>, designed for precision clearance of pathogenic CD20-positive B-cell compartments.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>Meet with HanchorBio at Jefferies APAC<\/strong><\/p>\n<p>Institutional investors, corporate partners, and other healthcare industry participants wishing to schedule a 1-on-1 meeting with HanchorBio may submit a request through the Jefferies APAC Healthcare Conference meeting portal or contact the Company directly at <a href=\"mailto:BD@HanchorBio.com\">BD@HanchorBio.com<\/a>.<\/p>\n<p>The inaugural Jefferies APAC Healthcare Conference is expected to convene more than 80 leading healthcare companies and facilitate more than 700 meetings, including one-on-one and small-group discussions between institutional investors and senior corporate management.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>About HanchorBio<\/strong><\/p>\n<p>HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company focused on inventing next-generation biologics for cancer and immune-mediated diseases using its proprietary FBDB\u2122 platform.<\/p>\n<p>HanchorBio\u2019s pipeline includes HCB101, its lead SIRP\u03b1-based innate immune checkpoint program; HCB301, a clinical-stage trispecific immunotherapy targeting SIRP\u03b1, PD-L1, and TGF-\u03b2 biology; HCB303, a next-generation trispecific program integrating SIRP\u03b1, PD-L1, and TIGIT\/PVR biology; and additional programs across oncology and immune-mediated diseases.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Forward-Looking Statements<\/strong><\/p>\n<p>This press release contains forward-looking statements, including statements regarding the clinical development and potential of HCB101, HCB301, HCB303, HCB206, and other product candidates; future development strategies; potential therapeutic characteristics of HanchorBio\u2019s product candidates; and the capabilities and potential of the FBDB\u2122 platform.<\/p>\n<p>These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those described. Development timelines, regulatory plans, clinical strategies and potential therapeutic applications may change as additional data become available and regulatory interactions occur. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HanchorBio announced that executive management will participate in the 2026 Jefferies APAC Healthcare Conference, taking place September 20\u201321, 2026, at Hilton Shanghai Zhangjiang Science Park in Shanghai.<\/p>\n","protected":false},"featured_media":2554,"template":"","news-category":[36],"class_list":["post-2553","news","type-news","status-publish","has-post-thumbnail","hentry","news-category-events"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news\/2553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media\/2554"}],"wp:attachment":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media?parent=2553"}],"wp:term":[{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news-category?post=2553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}